CDKN2A copy number and p16 expression in malignant pleural mesothelioma in relation to asbestos exposure

BMC Cancer

Table 3 MPM and controls analyzed in relation with tumor and stromal mark in p16 IHC staining

	Malignant pleural mesothelioma		Positive controls	Quality controls
p16 staining by tumor – stroma relation	High exposure^a n = 47^b,c	Low exposure^d n = 17^e	n = 26^f	n = 7
Tumor neg, Stroma neg
n (%)	17 (45)	7 (59)	1 (4%)	2 (~ 33%) ^h
p^g	0.774
Tumor pos, Stroma neg
n (%)	2 (5)	3 (25)	4 (15%)	2 (~ 33%)ⁱ
p^g	0.112
Tumor neg, Stroma pos
n (%)	15 (40)	1 (8)	1 (4%)	0 (0%)
p^g	0.048*
Tumor pos, Stroma pos
n (%)	4 (10)	1 (8)	20 (77%)	2 (~ 33%)^j
p^g	1.000

Epithelioid and biphasic malignant pleural mesothelioma and controls analyzed in relation with tumor and stromal mark in p16 immunohistochemical (IHC) staining. ^aPulmonary asbestos fiber count ≥1.0 × 10⁶ fibres per gram dry lung (f/g); ^bFor two cases, tumor stained positive but stroma could not be analyzed; ^cFor eight cases IHC staining was not available; ^dPulmonary asbestos fiber count 0–0.5 × 10⁶ f/g; ^eFor five cases IHC staining was not available; ^fPositive controls were serous ovarian carcinomas; ^gFisher’s Exact Test, two-tailed; ^hAdenocarcinoma of the lung and pleomorphic liposarcoma; ⁱSerous ovarian carcinoma and serous ovarian or peritoneal carcinoma, ^jSerous ovarian carcinoma and serous peritoneal carcinoma; for one serous ovarian or peritoneal carcinoma IHC staining was not available.

ISSN: 1471-2407